GSK’s gepotidacin has been put on the regulatory fast track in the US, raising hopes that it could be the first in a new class of oral antibiotic treatment for uncomplicated urinary tract infections (uUTIs) in over 20 years.
The US Food and Drug Administration has granted a priority review for gepotidacin and assigned a Prescription Drug User Fee...